Olokizumab information

Olokizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	IL6
Clinical data
ATC code	L04AC23 (WHO) ;
Identifiers
CAS Number	1007223-17-7 ;
ChemSpider	none;
UNII	PAI71R1D2W;
KEGG	D12487;
	(what is this?) (verify)

Olokizumab (OKZ) sold under the name Artlegia, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis and COVID-19. It is a humanized monoclonal antibody against the interleukin-6 (IL-6). IL-6 is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases. Olokizumab is the first interleukin-6 (IL-6) inhibitor approved for treatment of rheumatoid arthritis which blocks directly cytokine instead of its receptor.^[1] Olokizumab specifically binds to IL-6 at Site 3, blocking IL-6 ability to form hexameric complex.^[2] Olokizumab was developed by R-Pharm group, and was launched in 2020.^[3]

^ Abuelazm M, Ghanem A, Mahmoud A, Brakat AM, Elzeftawy MA, Mamdouh Fayoud A, et al. (June 2023). "The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis". Clinical Rheumatology. 42 (6): 1503–1520. doi:10.1007/s10067-023-06519-6. PMC 10202974. PMID 36792848.
^ Nasonov EL, Feist E (2022-11-10). "Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6)" [The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)]. Rheumatology Science and Practice (in Russian). 60 (5): 505–518. doi:10.47360/1995-4484-2022-505-518. ISSN 1995-4492.
^ "Государственный реестр лекарственных средств" [State register of medicinal products]. grls.rosminzdrav.ru (in Russian). Retrieved 2024-04-01.

[1] Abuelazm M, Ghanem A, Mahmoud A, Brakat AM, Elzeftawy MA, Mamdouh Fayoud A, et al. (June 2023). "The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis". Clinical Rheumatology. 42 (6): 1503–1520. doi:10.1007/s10067-023-06519-6. PMC 10202974. PMID 36792848.

[2] Nasonov EL, Feist E (2022-11-10). "Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6)" [The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)]. Rheumatology Science and Practice (in Russian). 60 (5): 505–518. doi:10.47360/1995-4484-2022-505-518. ISSN 1995-4492.

[grls-3] "Государственный реестр лекарственных средств" [State register of medicinal products]. grls.rosminzdrav.ru (in Russian). Retrieved 2024-04-01.

Olokizumab information

and 26 Related for: Olokizumab information

Olokizumab

Avacincaptad pegol

Dupilumab

Interleukin 2

ATC code L04

Ustekinumab

Secukinumab

Ixekizumab

Tocilizumab

Interleukin 6

Anakinra

Benralizumab

Interleukin 12

Theralizumab

Interleukin 23

Sarilumab

Mepolizumab

Interleukin 23 subunit alpha

Interleukin

Interleukin 17

Daclizumab

Guselkumab

Interleukin 40

Interleukin 33

Interleukin 10

Lebrikizumab